company-header-logo-quoin

 

Quoin Pharmaceuticals, Ltd.

Quoin Pharmaceuticals Ltd. is a clinical stage specialty pharmaceutical company dedicated to the development and commercialization of therapeutic products that treat rare and orphan diseases for which there are currently no approved treatments. Quoin’s lead product, QRX003, is a once daily, topical lotion to treat Netherton Syndrome, a rare hereditary skin disease. Clinical testing of QRX003, under an open IND, is targeted to commence in Q2, 2022.

Nasdaq: QNRX
IR Website: https://investors.quoinpharma.com/
Headquarters: Ashburn, Virginia

Quoin is a clinical stage specialty pharmaceutical company dedicated to the development and commercialization of therapeutic products that treat rare and orphan diseases for which there are currently no approved treatments. Quoin’s lead product, QRX003, is a once daily, topical lotion to treat Netherton Syndrome, a rare hereditary skin disease. Clinical testing of QRX003, under an open IND, is targeted to commence in Q2, 2022.

TALK TO MANAGEMENT

The Quoin Pharmaceuticals management team is always available to talk to current and potential investors. They are happy to answer any questions you may have and tell you what makes their story unique. Please fill out this form, and we will connect you shortly.

Summary

Press Releases

Investor Presentation

Stock Chart (Intraday)

Stock Chart (Historical)

Stock Detail

Business Description

Highlights

Lead Product

Core Technology Highlights

Market Opportunity

Netherton Syndrome and Its Unmet Needs

SEC Filings

Management Overview

Risks & Disclosures

quoin-logo-white

The Quoin Pharmaceuticals management and investor relations team is available to talk to current and potential investors. They're happy to answer your questions and tell you what makes their story unique. Please fill out this form, and we will connect you shortly.

• Directly hear the Quoin Pharmaceuticals story
• Ask your questions
• Submit the form below and someone will get in touch with you as soon as possible

Note: Company management or its representative can only discuss and disclose information that is already available in the public domain. They will do their best to clarify such information to the extent permitted by securities law and industry regulations.